SlideShare a Scribd company logo
1 of 1
Download to read offline
ISEI Abstract: Session theme number 7
Investigating the use of a Point of Care salivary IgG test in the
sporting environment
DUNBAR J, JEHANLI A, and BROWNE A.
IPRO Interactive Ltd; Wallingford, UK.
ABSTRACT
Introduction
The use of salivary diagnostics within the sporting community has gathered momentum in recent
years; with the identification of hormone levels to assist in the optimisation of workloads, or antibody
levels to assess individual recovery status and potential immune suppression. Immediate feedback
for coaching and support staff via a Point of Care (POC) test would give a significant time advantage
over standard laboratory techniques, which often reveal data to sporting squads only days later. This
paper assesses a new POC product developed by Ipro for the rapid determination of salivary IgG in
comparison to standard laboratory ELISA determination.
Methods
A total of 45 saliva samples were taken from a cohort of English Premier League Senior and Academy
soccer players (22.4 ±7.2 yrs) using IPRO OFC collection kits. The samples were taken during routine
monitoring: before training sessions. The same samples were assessed immediately on a POC Lateral
Flow Device (LFD) to determine salivary IgG concentrations and then taken to a laboratory for
subsequent analysis via ELISA within 4 hours of collection. The measurement range for ELISA was
1.75 - 105 µg/ml and POC test 1.6 - 120 µg/ml.
Results
Four samples exceded maximum values on both platforms and were excluded from the analysis. The
remaining salivary IgG concentrations measured via ELISA ranged from 7.26 - 57.54 µg/ml and with
the LFD from 2.26 - 51.81 µg/ml, with the mean difference 7.90 µg/ml. The relationship between the
salivary IgG values obtained using the ELISA and POC test was represented by the formula:
y = 0.8305x – 3.8109, with R2 0.8107.
Conclusion
The POC test used in the sporting environment showed good agreement with the ELISA method for
the determination of salivary IgG. Given the quick data turnaround and efficiency in terms of cost, it
represents a suitable alternative method for use in sports teams.
0.00
10.00
20.00
30.00
40.00
50.00
60.00
0.00 10.00 20.00 30.00 40.00 50.00 60.00
POCIgGµg/ml
ELISA IgG µg/ml

More Related Content

Similar to 2013 ISEI - Investigating the use of a Point of Care salivary IgG test in the sporting environment

44-150724PST_Peptalk_2013_AlphaLISA_immunoassays
44-150724PST_Peptalk_2013_AlphaLISA_immunoassays44-150724PST_Peptalk_2013_AlphaLISA_immunoassays
44-150724PST_Peptalk_2013_AlphaLISA_immunoassaysMichael A. Lomotan
 
Gardner, lynn (atlanta_3)[1][1]
Gardner, lynn (atlanta_3)[1][1]Gardner, lynn (atlanta_3)[1][1]
Gardner, lynn (atlanta_3)[1][1]ORALFLUIDLEADTEST
 
Gardner, lynn (atlanta_3)[1][1]
Gardner, lynn (atlanta_3)[1][1]Gardner, lynn (atlanta_3)[1][1]
Gardner, lynn (atlanta_3)[1][1]Eugene Elwell
 
Isac 2010 Poster Jay 042910 Final
Isac 2010 Poster Jay 042910 FinalIsac 2010 Poster Jay 042910 Final
Isac 2010 Poster Jay 042910 Finaljoropab1
 
UV Spectroscopic assay method development and Validation of Ciprofloxacin in ...
UV Spectroscopic assay method development and Validation of Ciprofloxacin in ...UV Spectroscopic assay method development and Validation of Ciprofloxacin in ...
UV Spectroscopic assay method development and Validation of Ciprofloxacin in ...Imran al
 
Pyrogen and its various test
Pyrogen and its various testPyrogen and its various test
Pyrogen and its various testPrachi Barbhaiya
 
PRINT THIS POSTER
PRINT THIS POSTERPRINT THIS POSTER
PRINT THIS POSTERJuhi Patel
 
OPG ELISA Assay Publication
OPG ELISA Assay PublicationOPG ELISA Assay Publication
OPG ELISA Assay PublicationNihal Sarikaya
 
Serum s100 b levels after meningioma surgery
Serum s100 b levels after meningioma surgerySerum s100 b levels after meningioma surgery
Serum s100 b levels after meningioma surgeryLAB IDEA
 
2015 PBL Assay Solutions
2015 PBL Assay Solutions2015 PBL Assay Solutions
2015 PBL Assay Solutionsstephenaparent
 
Reff HIV CBS OFT Panli.pptx
Reff HIV CBS OFT Panli.pptxReff HIV CBS OFT Panli.pptx
Reff HIV CBS OFT Panli.pptxAang Sutrisna
 
Validation of Opsonophagocytic assay for pnemococcal vaccine
Validation of Opsonophagocytic assay for pnemococcal vaccineValidation of Opsonophagocytic assay for pnemococcal vaccine
Validation of Opsonophagocytic assay for pnemococcal vaccinekishor kulkarni
 
Functions of a clinical laboratory
Functions of a clinical laboratoryFunctions of a clinical laboratory
Functions of a clinical laboratoryJohn Douglas
 
Method Development and Validation for Estimation of Oral Hypoglycaemic Drug D...
Method Development and Validation for Estimation of Oral Hypoglycaemic Drug D...Method Development and Validation for Estimation of Oral Hypoglycaemic Drug D...
Method Development and Validation for Estimation of Oral Hypoglycaemic Drug D...ijtsrd
 
Reducing Oxidative Stress | Revelar
Reducing Oxidative Stress | RevelarReducing Oxidative Stress | Revelar
Reducing Oxidative Stress | RevelarMyRevelar
 
Samriti Bedi CO-OP REFLECTION PRESENTATION- Northeastern University
Samriti Bedi CO-OP REFLECTION PRESENTATION- Northeastern UniversitySamriti Bedi CO-OP REFLECTION PRESENTATION- Northeastern University
Samriti Bedi CO-OP REFLECTION PRESENTATION- Northeastern UniversitySamriti Bedi
 
Poster 45 biochimie
Poster 45 biochimiePoster 45 biochimie
Poster 45 biochimieJIB Congress
 

Similar to 2013 ISEI - Investigating the use of a Point of Care salivary IgG test in the sporting environment (20)

44-150724PST_Peptalk_2013_AlphaLISA_immunoassays
44-150724PST_Peptalk_2013_AlphaLISA_immunoassays44-150724PST_Peptalk_2013_AlphaLISA_immunoassays
44-150724PST_Peptalk_2013_AlphaLISA_immunoassays
 
Gardner, lynn (atlanta_3)[1][1]
Gardner, lynn (atlanta_3)[1][1]Gardner, lynn (atlanta_3)[1][1]
Gardner, lynn (atlanta_3)[1][1]
 
Gardner, lynn (atlanta_3)[1][1]
Gardner, lynn (atlanta_3)[1][1]Gardner, lynn (atlanta_3)[1][1]
Gardner, lynn (atlanta_3)[1][1]
 
Isac 2010 Poster Jay 042910 Final
Isac 2010 Poster Jay 042910 FinalIsac 2010 Poster Jay 042910 Final
Isac 2010 Poster Jay 042910 Final
 
UV Spectroscopic assay method development and Validation of Ciprofloxacin in ...
UV Spectroscopic assay method development and Validation of Ciprofloxacin in ...UV Spectroscopic assay method development and Validation of Ciprofloxacin in ...
UV Spectroscopic assay method development and Validation of Ciprofloxacin in ...
 
Pyrogen and its various test
Pyrogen and its various testPyrogen and its various test
Pyrogen and its various test
 
PRINT THIS POSTER
PRINT THIS POSTERPRINT THIS POSTER
PRINT THIS POSTER
 
Biopra activities
Biopra activitiesBiopra activities
Biopra activities
 
OPG ELISA Assay Publication
OPG ELISA Assay PublicationOPG ELISA Assay Publication
OPG ELISA Assay Publication
 
Serum s100 b levels after meningioma surgery
Serum s100 b levels after meningioma surgerySerum s100 b levels after meningioma surgery
Serum s100 b levels after meningioma surgery
 
2015 PBL Assay Solutions
2015 PBL Assay Solutions2015 PBL Assay Solutions
2015 PBL Assay Solutions
 
2015 PBL Assay Solutions
2015 PBL Assay Solutions2015 PBL Assay Solutions
2015 PBL Assay Solutions
 
ELISA ( Enzyme linked immunosorbent assay)
ELISA ( Enzyme linked immunosorbent assay)ELISA ( Enzyme linked immunosorbent assay)
ELISA ( Enzyme linked immunosorbent assay)
 
Reff HIV CBS OFT Panli.pptx
Reff HIV CBS OFT Panli.pptxReff HIV CBS OFT Panli.pptx
Reff HIV CBS OFT Panli.pptx
 
Validation of Opsonophagocytic assay for pnemococcal vaccine
Validation of Opsonophagocytic assay for pnemococcal vaccineValidation of Opsonophagocytic assay for pnemococcal vaccine
Validation of Opsonophagocytic assay for pnemococcal vaccine
 
Functions of a clinical laboratory
Functions of a clinical laboratoryFunctions of a clinical laboratory
Functions of a clinical laboratory
 
Method Development and Validation for Estimation of Oral Hypoglycaemic Drug D...
Method Development and Validation for Estimation of Oral Hypoglycaemic Drug D...Method Development and Validation for Estimation of Oral Hypoglycaemic Drug D...
Method Development and Validation for Estimation of Oral Hypoglycaemic Drug D...
 
Reducing Oxidative Stress | Revelar
Reducing Oxidative Stress | RevelarReducing Oxidative Stress | Revelar
Reducing Oxidative Stress | Revelar
 
Samriti Bedi CO-OP REFLECTION PRESENTATION- Northeastern University
Samriti Bedi CO-OP REFLECTION PRESENTATION- Northeastern UniversitySamriti Bedi CO-OP REFLECTION PRESENTATION- Northeastern University
Samriti Bedi CO-OP REFLECTION PRESENTATION- Northeastern University
 
Poster 45 biochimie
Poster 45 biochimiePoster 45 biochimie
Poster 45 biochimie
 

2013 ISEI - Investigating the use of a Point of Care salivary IgG test in the sporting environment

  • 1. ISEI Abstract: Session theme number 7 Investigating the use of a Point of Care salivary IgG test in the sporting environment DUNBAR J, JEHANLI A, and BROWNE A. IPRO Interactive Ltd; Wallingford, UK. ABSTRACT Introduction The use of salivary diagnostics within the sporting community has gathered momentum in recent years; with the identification of hormone levels to assist in the optimisation of workloads, or antibody levels to assess individual recovery status and potential immune suppression. Immediate feedback for coaching and support staff via a Point of Care (POC) test would give a significant time advantage over standard laboratory techniques, which often reveal data to sporting squads only days later. This paper assesses a new POC product developed by Ipro for the rapid determination of salivary IgG in comparison to standard laboratory ELISA determination. Methods A total of 45 saliva samples were taken from a cohort of English Premier League Senior and Academy soccer players (22.4 ±7.2 yrs) using IPRO OFC collection kits. The samples were taken during routine monitoring: before training sessions. The same samples were assessed immediately on a POC Lateral Flow Device (LFD) to determine salivary IgG concentrations and then taken to a laboratory for subsequent analysis via ELISA within 4 hours of collection. The measurement range for ELISA was 1.75 - 105 µg/ml and POC test 1.6 - 120 µg/ml. Results Four samples exceded maximum values on both platforms and were excluded from the analysis. The remaining salivary IgG concentrations measured via ELISA ranged from 7.26 - 57.54 µg/ml and with the LFD from 2.26 - 51.81 µg/ml, with the mean difference 7.90 µg/ml. The relationship between the salivary IgG values obtained using the ELISA and POC test was represented by the formula: y = 0.8305x – 3.8109, with R2 0.8107. Conclusion The POC test used in the sporting environment showed good agreement with the ELISA method for the determination of salivary IgG. Given the quick data turnaround and efficiency in terms of cost, it represents a suitable alternative method for use in sports teams. 0.00 10.00 20.00 30.00 40.00 50.00 60.00 0.00 10.00 20.00 30.00 40.00 50.00 60.00 POCIgGµg/ml ELISA IgG µg/ml